van Rhijn, Norman http://orcid.org/0000-0001-6722-2757
Storer, Isabelle S. R.
Birch, Mike
Oliver, Jason D. http://orcid.org/0009-0001-5854-6861
Bottery, Michael J.
Bromley, Michael J. http://orcid.org/0000-0002-7611-0201
Funding for this research was provided by:
Wellcome Trust (219551/Z/19/Z, 226408/Z/22/Z, 221653/Z/20/Z)
RCUK | Medical Research Council (DTP)
Article History
Received: 23 February 2023
Accepted: 31 October 2023
First Online: 27 December 2023
Competing interests
: M. J. Bromley is a former employee of F2G Ltd (until 2007), the company that developed the antifungal olorofim. He has received historic funding for PhD studentships from F2G Ltd but has no current financial interest in F2G Ltd. M.B. and J.D.O. are employed by F2G Ltd. Experiments carried out at the University of Manchester were done independently and without input or incumbrance from F2G Ltd. F2G Ltd contribution was solely in relation to the IC<sub>50</sub> analysis of AfDHODH variants. All remaining authors declare no competing interests.